Top Markets
Coin of the day
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
Rang in aandelen #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Aandeelprijs
$5.47
Laatst gesynchroniseerd: 2026-08-14
Marktkapitalisatie
$7.99M
Verandering (1 dag)
6.21%
Verandering (1 jaar)
7.47%
Land
US
Handel CNS Pharmaceuticals, Inc. (CNSP)

Categorie

P/B-ratio voor CNS Pharmaceuticals, Inc. (CNSP)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van CNS Pharmaceuticals, Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor CNS Pharmaceuticals, Inc. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE